Credit Suisse Ag Ocugen, Inc. Transaction History

Credit Suisse Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$0.82 - $1.33 $126,322 - $204,889	-154,052 Reduced 69.38%	68,000 $57,000
Q4 2022 Feb 13, 2023	SELL	$1.11 - $1.87 $21,982 - $37,033	-19,804 Reduced 8.19%	222,052 $288,000
Q3 2022 Nov 10, 2022	BUY	$1.75 - $3.1 $134,356 - $238,002	76,775 Added 46.51%	241,856 $430,000
Q2 2022 Aug 12, 2022	BUY	$1.83 - $3.45 $1,324 - $2,497	724 Added 0.44%	165,081 $375,000
Q1 2022 May 16, 2022	BUY	$2.34 - $4.72 $21,296 - $42,956	9,101 Added 5.86%	164,357 $541,000
Q4 2021 Feb 14, 2022	BUY	$4.38 - $15.67 $114,484 - $409,582	26,138 Added 20.24%	155,256 $707,000
Q3 2021 Nov 12, 2021	BUY	$6.36 - $8.51 $86,031 - $115,114	13,527 Added 11.7%	129,118 $928,000
Q2 2021 Aug 16, 2021	BUY	$5.52 - $15.68 $520,900 - $1.48 Million	94,366 Added 444.6%	115,591 $928,000
Q1 2021 May 14, 2021	BUY	$1.66 - $15.81 $35,233 - $335,567	21,225 New	21,225 $144,000

124

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $167M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.